Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04403555
  4. Details
NCT04403555 Clinical Trial

Ivermectin as a Novel Therapy in COVID-19 Treatment

COVID Clinical Trial

Official title:
The Efficacy of Ivermectin in COVID-19 Treatment

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04403555
Other study ID # tanta covid treatment
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date June 1, 2020
Est. completion date December 1, 2020

Study information
Verified date July 2021
Source Tanta University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Efficacy of Ivermectin in COVID-19 treatment

Description:

Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 treatment

Recruitment information / eligibility
Status Completed
Enrollment 164
Est. completion date December 1, 2020
Est. primary completion date October 31, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - All Adult Patients aging from 20 to 65 years-old with COVID-19 confirmed by pharyngeal swab PCR. Exclusion Criteria: - Allergy or contraindication to the drugs used in the study. - Pregnant and lactating mothers. - Patients with cardiac problems.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Ivermectin
Ivermectin treatment

Locations
Country Name City State
Egypt Sherief Abd-Elsalam Tanta

Sponsors (1)
Lead Sponsor Collaborator
Tanta University

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary The number of patients with mortality Improvement of survival 1 month
Secondary Length of hospital stay Effect on the length of hospital stay 1 month
Secondary The need for mechanical ventilation Need for mechanical ventilation 1 month
See also
  Status Clinical Trial Phase
Terminated NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Active, not recruiting NCT04420676 - Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection N/A
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Completed NCT04425317 - Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients N/A
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Withdrawn NCT04456426 - Characteristics of Patients With COVID-19 in Meta State, Colombia
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Completed NCT04425720 - Use of Remote Monitoring for COVID-19 Patient N/A
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Completed NCT04419610 - RAS and Coagulopathy in COVID19 Early Phase 1
Completed NCT04546581 - Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) Phase 3
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Not yet recruiting NCT04524156 - COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2 N/A
Completed NCT04441710 - Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
Completed NCT04357834 - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting NCT04392427 - New Antiviral Drugs for Treatment of COVID-19 Phase 3
Terminated NCT04614025 - Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19 Phase 2
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2